Ho SN, Biggar SR, Spencer DM, Schreiber SL, Crabtree GR. Dimeric ligands define a role for transcriptional activation domains in reinitiation. Nature. 1996;382(6594):822-6. doi:10.1038/382822a0
Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science. 1996;273(5272):239-42.
Tai PK, Albers MW, McDonnell DP, Chang H, Schreiber SL, Faber LE. Potentiation of progesterone receptor-mediated transcription by the immunosuppressant FK506. Biochemistry. 1994;33(35):10666-71.
Van Duyne GD, Standaert RF, Karplus PA, Schreiber SL, Clardy J. Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin. J Mol Biol. 1993;229(1):105-24. doi:10.1006/jmbi.1993.1012
Starzl TE, Schreiber SL, Albers MW, Porter KA, Foglieni CS, Francavilla A. Hepatotrophic properties in dogs of human FKBP, the binding protein for FK506 and rapamycin. Transplantation. 1991;52(4):751-3.
Jin YJ, Albers MW, Lane WS, Bierer BE, Schreiber SL, Burakoff SJ. Molecular cloning of a membrane-associated human FK506- and rapamycin-binding protein, FKBP-13. Proc Natl Acad Sci U S A. 1991;88(15):6677-81.
Hultsch T, Albers MW, Schreiber SL, Hohman RJ. Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription. Proc Natl Acad Sci U S A. 1991;88(14):6229-33.
Bierer BE, Schreiber SL, Burakoff SJ. The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation. Eur J Immunol. 1991;21(2):439-45. doi:10.1002/eji.1830210228
Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature. 1995;377(6548):441-6. doi:10.1038/377441a0
Stockwell BR, Schreiber SL. TGF-beta-signaling with small molecule FKBP12 antagonists that bind myristoylated FKBP12-TGF-beta type I receptor fusion proteins. Chem Biol. 1998;5(7):385-95.